Table 1. Demographics of Cohorts.
| Cohort | P Valuea | PASC Hospitalized | P Value | |||
|---|---|---|---|---|---|---|
| PASC | RC | PASC-RC | Yes | No | Yes-No | |
| Number of participantsb | 20 | 20 | 8Δ | 12 | ||
| Female | 10 (50) | 10 (50) | >0.99 | 2 (25) | 8 (75) | 0.17 |
| Male | 10 (50) | 10 (50) | >0.99 | 6 (75) | 4 (25) | 0.17 |
| Median time to samplec (Range) | 212 (64–396) | 197Δ (13–289) | 0.08 | 184.5 (31–383) | 183 (45–332) | 0.79 |
| Median Age (Range) | 53 (22–69) | 50 (27–73) | 0.18 | 60 (49–69) | 50 (22–62) | 0.01 |
| ICU Admission | 6 (32) | NAd | NA | 6 (75) | NA | NA |
| Race and Ethnicity | ||||||
| White | 17 (85) | 18 (90) | >0.99 | 6 (75) | 11 (92) | >0.99 |
| Black | 2 (10) | 2 (10) | >0.99 | 1 (13) | 1 (8) | >0.99 |
| American Indian/Alaska Native | 0 (0) | 2 (10) | 0.49 | 0 (0) | 0 (0) | >0.99 |
| Other | 1 (5) | 0 (0) | >0.99 | 1 (13) | 0 (0) | >0.99 |
| Hispanic or Latin Origin | 5 (25) | 3 (15) | 0.69 | 3 (38) | 2 (17) | 0.60 |
| Underlying Medical Condition | ||||||
| Any | 10 (50)Δ | 8 (40) | 0.75 | 4 (50) | 6 (50) | >0.99 |
| Hypertension | 7 (35) | 2 (10) | 0.13 | 2 (25) | 4 (33) | >0.99 |
| Pulmonary Disease | 2 (10) | 2 (10) | >0.99 | 0 (0) | 2 (17) | 0.50 |
| Cardiac Disease | 0 (0) | 1 (5) | >0.99 | 0 (0) | 0 (0) | >0.99 |
| Immune System Disease | 1 (5) | 1 (5) | >0.99 | 0 (0) | 1 (8) | >0.99 |
| Cancer | 1 (5) | 0 (0) | >0.99 | 0 (0) | 1 (8) | >0.99 |
| Kidney Disease | 1 (5) | 1 (5) | >0.99 | 0 (0) | 1 (8) | >0.99 |
| Metabolic Disease | 5 (25) | 1 (5) | 0.18 | 4 (50) | 1 (8) | 0.11 |
| Medications during Hospitalization | ||||||
| Convalescent Plasma | 3 (15) | NA | NA | 3 (38) | NA | NA |
| Hydroxychloroquine | 4 (20) | NA | NA | 4 (50) | NA | NA |
| Remdesivir | 4 (20) | NA | NA | 4 (50) | NA | NA |
| Dexamethasone | 4 (20) | NA | NA | 4 (50) | NA | NA |
| Tocilizumab | 0 (0) | NA | NA | 0 (0) | NA | NA |
aMann-Whitney tests were used to determine differences between groups where P<0.05 is considered significant.
bAll values are number of participants with the percentage of the cohort in parentheses unless otherwise specified.
cMedian number of days from first reported symptom to collection of blood.
dNA = Not applicable.
ΔIndicates stratification analyses were performed demonstrating these differences do not influence SARS-CoV-2-specific T cell frequencies and levels of plasma IL-6.